Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.
This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.
Rovaris
M
M
Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy.
Codella
M
M
Moiola
L
L
Ghezzi
A
A
Zaffaroni
M
M
Mancardi
G
G
Capello
E
E
Sardanelli
F
F
Comi
G
G
Filippi
M
M
D000293:Adolescent; D000328:Adult; D005682:Gadolinium / Q000008:administration & dosage; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology*; D010455:Peptides / Q000008:administration & dosage*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D005682:Gadolinium